Posted by: Market Watch in Market Information 1 min in the past Novavax Inc. launched extra intensive information on its Section 1 trial of
Novavax Inc. launched extra intensive information on its Section 1 trial of a vaccine for COVID-19 Wednesday, and shares rose about 4% in after-hours buying and selling. Novavax beforehand launched findings from the research that mentioned the vaccine candidate induced immune responses and was well-tolerated, however extra extra information from the research was printed Wednesday in The New England Journal of Drugs. “The speedy publication of Section 1 outcomes from our trial in a prestigious peer-reviewed journal displays each the significance of the info and the pressing want for an efficient vaccine to sluggish the COVID-19 pandemic,” Novavax’s president of analysis and improvement, Gregory Glenn, mentioned in a information launch. After closing with a 2.1% decline at $102.90 in Wednesday’s common session, shares topped $107 in after-hours buying and selling following launch of the data. Novavax is certainly one of no less than 23 corporations engaged on options to COVID-19 amid a world pandemic. Novavax shares have gained almost 2,500% to this point this yr.Market Pulse Tales are Fast-fire, quick information bursts on shares and markets as they transfer. Go to MarketWatch.com for extra data on this information.
Learn Full Story
